S&P Cuts Amsurg (AMSG) to 'B+'; Cites Increased Debt Burden

Go back to S&P Cuts Amsurg (AMSG) to 'B+'; Cites Increased Debt Burden

Moody's Cuts Amsurg (AMSG) to 'Ba3'; Notes Leverage Increase on Sheridan Acquisition

June 30, 2014 9:56 AM EDT

Moody's Investors Service downgraded AmSurg Corp's (Nasdaq: AMSG) Corporate Family Rating to B1 from Ba3 and the Probability of Default Rating to B1-PD from Ba3-PD. Concurrently, AmSurg's existing senior unsecured notes are downgraded to B3 from Ba3. In addition, Moody's assigned a Ba2 rating to the company's new $1.4 billion senior secured credit facilities, consisting of a $300 million revolving credit facility expiring in 2019, and a $1.1 billion senior secured term loan B due 2021. Moody's has also assigned a B3 rating to the company's new $880 million senior unsecured notes. The rating outlook is stable. The action... More

Amsurg (AMSG) Plans $880M Senior Unsecured Notes Offering

June 30, 2014 6:50 AM EDT

Amsurg (Nasdaq: AMSG) announced that it has launched its offering of approximately $880 million aggregate principal amount of senior unsecured notes due 2022 (the Notes). The closing of the offering of the Notes is conditioned upon the closing of AMSURGs previously announced acquisition of Sheridan Healthcare (the Sheridan Transaction).

AMSURG intends... More